American Journal of Cardiovascular Drugs

Papers
(The H4-Index of American Journal of Cardiovascular Drugs is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Current Overview on Hypercoagulability in COVID-19124
COVID-19 Pandemic: Cardiovascular Complications and Future Implications91
Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis32
Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia29
A Critical Review of the Efficacy and Safety of Inclisiran26
Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)23
Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide22
The Association Between the Use of Statins and Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-analysis20
Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections20
Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis19
Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial—The RIWA study19
Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-1919
Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?17
Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes17
Non-adherence to Thromboprophylaxis Guidelines in Atrial Fibrillation: A Narrative Review of the Extent of and Factors in Guideline Non-adherence17
Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis16
Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis16
0.041818141937256